The oncogenic role of JC virus T antigen in lens tumors without cell specificity of alternative splicing of its intron

Wenfeng Gou(Chinese Academy of Medical Sciences & Peking Union Medical College), Hua‐chuan Zheng(Jinzhou Medical University), Shuang Zhao(Jiangnan University), Xuefeng Yang(Zunyi Medical University), Yunpeng Liu(Shenyang Institute of Automation), Dao-fu Shen(First Affiliated Hospital of Liaoning Medical University), Jun-Sheng Luo(First Affiliated Hospital of Liaoning Medical University), Hongzhi Sun(First Affiliated Hospital of Xi'an Jiaotong University)
Oncotarget
March 10, 2015
10.18632/oncotarget.3507
Cited by 10

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The molecular mechanisms of chemoresistance in cancers
|Oncotarget|2017|599
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417